Function
Locations
Rate-limiting, feedback-regulated (FXR/bile-acid) committed entry to the classic (neutral) bile-acid pathway. Deficiency -> hypercholesterolemia/gallstones.
The first phase of bile-acid biosynthesis modifies the cholesterol steroid nucleus, producing the 7-alpha-hydroxylated, 3-oxo, 5-beta-reduced cholestane intermediates that are later shortened in the side chain to the C24 bile acids. Two entry routes converge: the CLASSIC (neutral) pathway begins with cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting, feedback-regulated enzyme that hydroxylates cholesterol at C7-alpha; the ACIDIC (alternative) pathway begins when oxysterols (25- and 27-hydroxycholesterol, from CH25H/CYP27A1) are 7-alpha-hydroxylated by oxysterol 7-alpha-hydroxylase (CYP7B1). The 7-alpha-hydroxy sterols are then oxidised and isomerised by the 3-beta-hydroxy-Delta5-C27- steroid dehydrogenase HSD3B7 to the 3-oxo-Delta4 intermediate (7-alpha-hydroxy-4-cholesten- 3-one), and the Delta4 double bond is reduced to the 5-beta configuration by steroid 5-beta-reductase (AKR1D1), giving the cis-fused (5-beta) A/B ring junction characteristic of bile acids. (CYP8B1 branches here to specify cholic vs chenodeoxycholic acid.) Inherited defects: CYP7A1 deficiency (hypercholesterolemia/gallstones); CYP7B1 deficiency (hereditary spastic paraplegia type 5A and severe neonatal liver failure); HSD3B7 deficiency (congenital bile acid synthesis defect type 1); and AKR1D1 deficiency (bile acid synthesis defect type 2) — the HSD3B7/AKR1D1 defects present as neonatal cholestasis with fat-soluble-vitamin malabsorption.
All recommended fields populated.
✗ none found
No MODULE:bile_acid_synthesis_ring_modification deep-research report alongside the module YAML.
✓ every leaf node grounds to a representative protein.
✓ every declared conforms_to bundle matches its template motif.
3 gene-function check(s) reflected in core functions · 0 conflict(s) · 5 evidence or coverage gap(s) (8 comparison(s))
Retained noncore functions are reported separately; they do not require promotion to core functions. Support from representative genes does not establish conservation across the whole family. Missing reviews or identifiers leave a claim unverified.
| Annoton | Participant | Function | Assessment |
|---|---|---|---|
| cyp7a1_activity | CYP7A1 (human) UniProtKB:P22680 Family Representative |
cholesterol 7-alpha-monooxygenase activity GO:0008123 |
Core Supported
The GO molecular function is reflected in core_functions (exact term or a reviewed subclass). |
| cyp7b1_activity | CYP7B1 (human) UniProtKB:O75881 Family Representative |
oxysterol 7-alpha-hydroxylase activity GO:0008396 |
Review Disagreement
The review removes, modifies, or marks this term over-annotated and provides no retained/core support. Review the rationale; rejection of an evidence row alone is not a biological NOT. |
| hsd3b7_activity | HSD3B7 (human) UniProtKB:Q9H2F3 Family Representative |
3-beta-hydroxy-Delta5-steroid dehydrogenase (NAD+) activity GO:0003854 |
Core Supported
The GO molecular function is reflected in core_functions (exact term or a reviewed subclass). |
| akr1d1_activity | AKR1D1 (human) UniProtKB:P51857 Family Representative |
Delta4-3-oxosteroid 5beta-reductase activity GO:0047787 |
Core Supported
The GO molecular function is reflected in core_functions (exact term or a reviewed subclass). |
| cyp7a1_activity | Cytochrome P450 family (CYP7A1/CYP7B1) PANTHER:PTHR24304 Family |
cholesterol 7-alpha-monooxygenase activity GO:0008123 |
Family Review Missing
No supported structured family review is available for PANTHER:PTHR24304. |
| cyp7b1_activity | Cytochrome P450 family (CYP7A1/CYP7B1) PANTHER:PTHR24304 Family |
oxysterol 7-alpha-hydroxylase activity GO:0008396 |
Family Review Missing
No supported structured family review is available for PANTHER:PTHR24304. |
| hsd3b7_activity | 3-beta-hydroxysteroid dehydrogenase family (HSD3B7) PANTHER:PTHR10366 Family |
3-beta-hydroxy-Delta5-steroid dehydrogenase (NAD+) activity GO:0003854 |
Family Review Missing
No supported structured family review is available for PANTHER:PTHR10366. |
| akr1d1_activity | Aldo-keto reductase / steroid 5-beta-reductase family (AKR1D1) PANTHER:PTHR11732 Family |
Delta4-3-oxosteroid 5beta-reductase activity GO:0047787 |
Family Scope Restricted
GO:0047787 is SUBFAMILY_ONLY; this family grounding does not establish the allowed subfamily scope. AKR1D1 (SF211); bile_acid_biosynthesis and bile_acid_synthesis_ring_modification select the base family. |
2 complete review(s) · 0 with deep research · 0 missing review · 4 reviewed but lacking deep research
| Gene | Review | Complete | Deep research |
|---|---|---|---|
| AKR1D1 P51857 | ✓ | 37/41 | ✗ |
| CYP7A1 P22680 | ✓ | ✓ | ✗ |
| CYP7B1 O75881 | ✓ | 30/32 | ✗ |
| HSD3B7 Q9H2F3 | ✓ | ✓ | ✗ |
The ring-modification phase of bile-acid biosynthesis grounded to the human enzymes CYP7A1 (UniProtKB:P22680, GO:0008123, EC 1.14.14.23), CYP7B1 (O75881, GO:0008396, EC 1.14.14.29), HSD3B7 (Q9H2F3, GO:0003854, EC 1.1.1.181) and AKR1D1 (P51857, GO:0047787, EC 1.3.1.3). GO molecular-function terms were taken from the human GOA records; Reactome reaction ids and titles were verified against the local reactome cache. CYP7A1 and CYP7B1 share the P450 family PTHR24304 (each represented by its own gene); HSD3B7 and AKR1D1 use their own family selectors. Two entry routes converge: the classic/neutral pathway (CYP7A1, the rate-limiting committed step) and the acidic/alternative pathway (CYP7B1, on oxysterols from CYP27A1/CH25H); both feed HSD3B7 then AKR1D1. CYP8B1 (12-alpha-hydroxylase, not in this batch) branches at the HSD3B7/AKR1D1 intermediates to specify cholic vs chenodeoxycholic acid. Downstream, the 5-beta-cholestane intermediates undergo side-chain oxidation (CYP27A1) and peroxisomal beta-oxidation (AMACR, ACOX2, then conjugation by SLC27A5/BAAT) to the mature C24 bile acids (a separate module, to follow). Disorders: CYP7A1 (hypercholesterolemia/gallstones); CYP7B1 (SPG5A / neonatal liver failure); HSD3B7 (bile acid synthesis defect type 1); AKR1D1 (bile acid synthesis defect type 2).
Rate-limiting, feedback-regulated (FXR/bile-acid) committed entry to the classic (neutral) bile-acid pathway. Deficiency -> hypercholesterolemia/gallstones.
Committed 7-alpha-hydroxylation of oxysterols in the acidic (alternative) bile-acid pathway. Deficiency -> hereditary spastic paraplegia type 5A / neonatal liver failure.
Oxidises the 3-beta-hydroxyl and isomerises the Delta5 double bond of the 7-alpha-hydroxy sterols to the 3-oxo-Delta4 intermediate (shared by both entry routes). Deficiency = bile acid synthesis defect type 1.
Reduces the Delta4 double bond to the 5-beta configuration, giving the cis-fused A/B ring junction characteristic of bile acids (also 5-beta-reduces steroid hormones). Deficiency = bile acid synthesis defect type 2.